Illumina Inc. received FDA approval for its Extended RAS Panel, a next-generation sequencing (NGS) test kit to be used with Amgen Inc.'s colorectal cancer drug, Vectibix. The San Diego-based company's companion diagnostic can run on the Illumina Miseqdx system and will enable U.S. laboratories to help clinicians identify which patients are eligible for treatment of metastatic colorectal cancer (mCRC ) with Vectibix (panitumumab).